The aim of the study was to assess the effect of 6-month administration of atorvastatin on hepcidin and hemojuvelin levels, inflammatory parameters and iron metabolism in patients with stages 3 and 4 CKD. This evidence concerns the gene HAMP and chronic kidney disease.